The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Bayer; Eisai; MSD; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; MSD; Roche
Research Funding - Eisai; MSD
Travel, Accommodations, Expenses - Ipsen; Novartis
Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT.
 
Ari David Baron
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen Oncology; Lilly
 
Carlos López López
Honoraria - Advanced Accelerator Applications; AstraZeneca; Bayer; Bristol Myers Squibb; Eisai; Ipsen; Merck; MSD Oncology; Novartis; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Eisai; Ipsen; Merck; Pfizer; Roche; Sanofi; SERVIER
Research Funding - Amgen; AstraZeneca Spain; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Ipsen; Merck; Merck Sharp & Dohme; Roche; Sanofi
Travel, Accommodations, Expenses - Amgen; Ipsen; Merck; Pfizer; Roche; SERVIER
 
Stephen Lam Chang
No Relationships to Disclose
 
Fabio Piscaglia
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exact Sciences; Ipsen; Roche; Roche; Tiziana Life Sciences
Speakers' Bureau - Bracco Diagnostics; Eisai; ESAOTE; MSD; Samsung
 
Zahra Ramji
Employment - Eisai
 
Min Ren
Employment - Eisai
 
Kasey Estenson
Employment - Eisai
 
Arndt Vogel
Honoraria - Advanced Accelerator Applications/Imaging Equipment Ltd; Amgen; AstraZeneca/MedImmune; BeiGene; Boehringer Pharma GmbH; Boston Scientific; Bristol-Myers Squibb; Daichi-Sankyo; Eisai; GlaxoSmithKline; Incyte; Ipsen; Janssen; Lilly; MSD; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Sirtex Medical; Taiho Oncology; TERUMO
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Boehringer Pharma GmbH; BTG; Daichi-Sankyo; EISAI; Incyte; IPSEN; Lilly; Novartis; Pierre Fabre; Roche; Sirtex Medical; Taiho Oncology; Taiho Oncology; Terumo
Research Funding - Novartis
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Lilly; MSD; Roche
 
Pierre Gholam
Honoraria - AstraZeneca; Eisai; Exelixis; Genentech
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Genentech
Speakers' Bureau - AstraZeneca; Eisai; Exelixis; Genentech
Research Funding - Galectin Therapeutics; Intercept Pharmaceuticals; Inventiva Pharma; Novo Nordisk